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Abstract
Purpose The extent to which smoking is associated with thyroid stimulating hormone (TSH), free thyroxine (FT4), and free
triiodothyronine (FT3) when taking account of clinical variables including alcohol consumption is unclear. We aimed to
determine associations of TSH, FT4, and FT3 levels with current smoking.
Methods A cross-sectional study was performed in 5766 euthyroid participants (Prevention of Renal and Vascular End-
Stage Disease cohort). Current smoking was determined by self-report, categorized as never, former, and current (≤20 and
>20 cigarettes per day). Smoke exposure was determined by urinary cotinine.
Results Current smoking of ≤20 and >20 cigarettes per day was associated with lower TSH and higher FT3 levels. FT4
levels were higher in subjects smoking <20 cigarettes per day vs. never and former smokers. Current smokers also consumed
more alcohol. Multivariable linear regression analyses adjusted for age, sex, anti-TPO autoantibody positivity, alcohol
consumption, and other variables demonstrated that lower TSH, higher FT4 and higher FT3 were associated with smoking
≤20 cigarettes per day vs. subjects who never smoked (P < 0.001, P= 0.018, and P < 0.001, respectively) without a further
significant incremental effect of smoking >20 cigarettes per day. In agreement, TSH was inversely, whereas FT4 and FT3
levels were positively associated with urinary cotinine (P < 0.001 for each). In contrast, alcohol consumption >30 g per day
conferred higher TSH and lower FT3 levels.
Conclusions Cigarette smoking is associated with modestly higher FT4 and FT3, and lower TSH levels, partly opposing
effects of alcohol consumption.
Keywords Alcohol consumption ● Antiperoxidase autoantibodies ● Cigarette smoking ● FT4 ● FT3 ● TSH
Introduction
Disorders in thyroid function are very common in the
general population [1, 2], and it is increasingly appreciated
that variations in thyroid function, as inferred from circu-
lating levels of thyroid stimulating hormone (TSH), free
thyroxine (FT4), and free triiodothyronine (FT3) within
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their respective reference ranges, may impact on a number
of health issues including atherosclerosis susceptibility
[3–6]. Although not unequivocally reported, it is also
noteworthy that variations in thyroid function within the
reference range could affect life expectancy [7, 8]. It is,
therefore, relevant to better understand the impact of life
style factors on thyroid function status.
It has long been recognized that cigarette smoking may
affect thyroid function, conceivably attributable to exposure
to toxic metabolites, enhanced sympathetic nervous activity,
or by affecting thyroid-directed autoimmune responses
[4, 9, 10]. In the eighties of the last century, it was already
documented that smoking cessation elicits a rise in TSH and
a decrease in T4 [11]. Indeed, with some exceptions, evi-
dence has accumulated since that cigarette smoking is
associated lower TSH and higher FT4 levels, whereas T3
and FT3 were also found to be higher or unaltered
[9, 10, 12, 13]. In addition, using serum or urinary cotinine
as a measure of nicotine exposure it was found that smoke
exposure is associated with lower TSH levels [14, 15].
Among other life style factors, alcohol consumption has
been suggested to lower FT4 [16]. Moreover, FT4 and FT3
levels are decreased in alcohol abusers after alcohol with-
drawal [17, 18]. Given that cigarette smoking may fre-
quently coincide with more heavy alcohol consumption
[18, 19], it is plausible to take account of alcohol use when
evaluating the association of cigarette smoking with thyroid
hormone levels. However, epidemiological surveys on the
effect of smoking on thyroid function parameters thus far
did not comprehensively assess the extent to which such
associations are independent of alcohol consumption and
other relevant characteristics.
For this reason the present study was initiated to deter-
mine the association of cigarette smoking assessed by self-
report as well as by urinary cotinine concentrations with
TSH, FT4, and FT3 taking account of alcohol consumption,
as well as other clinical and laboratory covariates in the
Prevention of Renal and Vascular End-Stage Disease
(PREVEND) cohort, a large and comprehensively char-
acterized population from the north of the Netherlands.
Materials and methods
Study population
The study was performed in the frame of the PREVEND
cohort study, which investigates vascular and renal damage
among predominantly white inhabitants of the city of
Groningen, The Netherlands, as reported in detail elsewhere
[19–23]. The study was approved by the Medical Ethics
Committee of the University Medical Center Groningen and
conformed to the principles outlined in the Declaration of
Helsinki. All participants gave written informed consent.
Briefly, in 1997–1998, all inhabitants of the city of Gro-
ningen, aged 28–75 years, were sent a short questionnaire
on demographics and cardiovascular morbidity and a vial to
collect an early morning urine sample (n= 85,421). Preg-
nant women and diabetic subjects using insulin were
excluded. Altogether 40,856 subjects responded (47.8%),
and their urinary albumin concentration was determined.
Subjects with a urinary albumin concentration ≥10 mg/L
(n= 7768) were invited to participate, of whom 6000 were
enrolled. In addition, a randomly selected group with a
urinary albumin concentration <10 mg/L (n= 3394) was
invited to participate in the cohort, of whom 2592 were
enrolled. The initial study population was comprised of
8592 subjects who completed the total screening program.
For the present study, we used data from participants who
completed the second screening round (2001–2003; n=
6894), excluding those with missing values for smoking
behavior, thyroid function tests, as well as those who were
not euthyroid (see Measurements and Definitions) and those
using thyroid hormones, antithyroid drugs, amiodarone, or
lithium carbonate. This left a cohort of 5766 participants
with sufficient information for analysis (Fig. 1).
Measurements and definitions
Euthyroidism was defined as TSH, FT4, and FT3 levels all
within the euthyroid reference range (TSH: 0.27–4.20 mU/L;
FT4: 12–22 pmol/L; FT3:3.1–6.8 pmol/L). Cigarette smok-
ing was estimated by questionnaire, and was categorized as
(i) never; (ii) former; (iii) current ≤20 cigarettes per day, and
(IV) current >20 cigarettes per day. In addition, urinary
cotinine concentrations were measured. Former smokers
were subjects who were nonsmokers at the time of the
second screening round but had ever smoked in their life;
current smokers were those who reported smoking at this
screening. Alcohol intake was estimated by using predefined
categories covering a time period of one month [19, 22].
Alcohol intake was then calculated as alcoholic drinks
per day with one drink being considered to be equivalent to
10 g of alcohol, regardless of the type of beverage [19].
Alcohol intake was categorized in (i) no/rarely; (ii) 0.1–10 g
per day (occasional to light); (iii) 10–30 g per day (moder-
ate), and (IV) >30 g per day (heavy).
The presence of a self-reported history of myocardial
infarction, percutaneous coronary intervention, coronary
artery bypass surgery, stroke, or the diagnosis of narrowing
of one or both carotid arteries was defined as cardiovascular
disease. Type 2 diabetes mellitus was defined as a fasting
serum glucose concentration >7.0 mmol/L, a nonfasting
serum glucose concentration >11.1 mmol/L, a self-report
of a physician diagnosis, or the use of glucose-lowering
drugs [23].
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Information on medication use was combined with
information from IADB.nl, a data base containing infor-
mation of prescribed medication in public pharmacies in
The Netherlands (http://www.iadb.nl/) [24]. Body mass
index (BMI) was calculated as weight (kg) divided by
height squared (m). Blood pressure was measured using an
automatic device (Dinamap XL model 9300 series;
Johnson-Johnson Medical, Tampa, FL, USA). Urinary
albumin excretion (UAE) was measured in two consecutive
24 h urine collections after oral and written instruction. The
participants were asked to avoid heavy exercise as much as
possible during the urine collection. Subjects were also
instructed to postpone their urine collection in case of
urinary tract infection, menstruation, or fever. The UAE
results were averaged for analysis. Estimated glomerular
filtration rate (eGFR) was calculated applying the combined
creatinine cystatin C-based Chronic Kidney Disease Epi-
demiology Collaboration equation [25]. The participants
were instructed to have their blood samples being taken in
the morning after an overnight fasting period.
Laboratory methods
Venous blood samples were obtained after 15 min rest.
Venous plasma and serum samples were obtained by cen-
trifugation at 1400 × g for 15 min at 4 °C. Serum glucose
was measured shortly after blood sampling. Ethylenedia-
minetetraacetic acid anticoagulated plasma and heparinized
plasma and serum was obtained by centrifugation at 4 °C,
and stored at −80 °C until analysis. Cotinine concentrations
were measured with with Enzyme Multiplied Immunoassay
Technique on the Abbott Architect c8000 system (Abbott
Laboratories, Abbott Park, IL, USA). Serum TSH, FT4,
FT3, and antithyroid peroxidase (anti-TPO) autoantibodies
were determined using the Roche Modular E170 Analyzer
electrochemiluminescent immunoassays (Roche Diag-
nostics, Mannheim, Germany). Anti-TPO autoantibodies
were considered positive using a cut-off value as indicated
by the supplier (≥35 kU/L). Twenty-four hour urinary
cotinine levels were measured with Enzyme Multiplied
Immunoassay Technique on the Abbott Architect
c8000 system (Abbott Laboratories, Abbott Park, IL).
Total cholesterol was measured on an automatic analyzer
(MEGA; Merck, Darmstadt, Germany) using the
CHOD–PAP-method. Glucose was measured using Kodak
Ektachem dry chemistry (Eastman Kodak, Rochester, New
York, USA). HDL cholesterol and triglycerides were
determined using the nuclear magnetic resonance (NMR)-
derived LP4 lipoprotein profile deconvolution algorithm as
described [26]. To this end NMR spectra were acquired on a
Vantera® Clinical Analyzer at LabCorp (Morrisville, NC,
USA). Serum creatinine was measured by an enzymatic
method on a RocheModular analyzer (Roche Diagnostics,
Mannheim, Germany). Serum cystatin C was measured by
Gentian Cystatin C Immunoassay (Gentian AS, Moss,
Norway) on a Modular analyzer (Roche Diagnostics).
Fig. 1 Flowchart depicting
PREVEND participants
included or excluded for the
purposes of this study
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Urinary albumin was measured by nephelometry (Dade
Behring Diagnostic, Marburg, Germany) [19].
Statistical analyses
Data analysis was performed using IBM SPSS software
(version 23.0, SPSS Inc., USA). Normally distributed data
are given as mean ± SD and nonparametrically distributed
data are presented as median (interquartile range). Catego-
rical variables are given as numbers and %. Anti-TPO
autoantibody titers (as continuous variable), TSH, trigly-
cerides, urine cotinine, and UAE were natural logarithm
(loge) transformed in order to achieve approximately normal
distributions. Differences in continuous variables between
categories of cigarette smoking were determined by Ana-
lysis of Variance with subsequent Bonferroni procedure to
correct for multiple comparisons. Differences in TSH, FT4,
and FT3 according to anti-TPO antibody status were
determined by unpaired T-tests. Proportions of dichotomous
variables across categories of cigarette smoking were
determined by χ2 tests. Pearson correlation coefficients were
calculated to determine univariate relationships. Multi-
variable linear regression analyses were used to discern the
independent association of current cigarette smoking with
TSH, FT4, and FT3. In these analyses, the category “never
smoked” was used as the reference category. In these ana-
lyses, we also used categorized alcohol consumption as
variable with the category “no/rarely” as reference. In
addition, analyses were repeated with urinary cotinine data
instead of self-reported smoking status. In these analyses,
urinary cotinine concentrations of 0 were set at 0.01 to
allow for loge transformation. Standardized regression
coefficients (β) were used to discern the strength of asso-
ciations of current smoking (≤ and >20 cigarettes per day)
with TSH, FT4, and FT3. Two-sided P-values < 0.05 were
considered significant.
Results
The clinical and laboratory characteristics of the participants
are shown in Table 1. Of the 5766 participants, 29.0% had
never smoked, 42.2% were former smokers, 24.9%
smoked ≤20 cigarettes per day, and 3.9% smoked >20
cigarettes per day. Urinary cotinine concentrations, mea-
sured in 5722 subjects, were highest in subjects who
smoked >20 cigarettes per day, and virtually absent in never
smokers and former smokers. Current smokers were
younger than former smokers and more likely to be men.
There were also differences in hemodynamics across the
four groups, with systolic blood pressure being lower in
current smokers vs. former smokers and pulse rate being
highest in subjects who smoked >20 cigarettes per day. The
most frequent use of antihypertensive and lipid lowering
drug was observed in the group of former smokers. Alcohol
consumption was lowest in subjects who never smoked and
highest in subjects who smoked >20 cigarettes per day.
eGFR was lowest and UAE was highest in former smokers.
Total cholesterol was highest and HDL cholesterol was
lowest in subjects who smoked ≤20 cigarettes per day,
whereas triglycerides were lowest in subjects who smoked
>20 cigarettes per day. As shown in Table 1, TSH levels
were lower in both groups of smokers vs. never and former
smokers. FT4 levels were higher in subjects who
smoked ≤20 cigarettes per day vs. never and former smo-
kers, whereas FT3 levels were highest in both groups of
smokers vs. never and former smokers. Anti-TPO antibody
titers were highest in current smokers. The highest pre-
valence of positive anti-TPO antibodies was observed in
subjects who smoked >20 cigarettes per day.
TSH was higher, whereas FT4 and FT3 levels were
lower in women vs. men (women (n= 2768): TSH 1.65
(1.14–2.32) mU/L, FT4 15.5 ± 1.8 pmol/L, and FT3 4.7 ±
0.5 pmol/L vs. men (n= 3008): TSH 1.50 (1.08–2.08) mU/L,
FT4 16.0 ± 1.9 pmol/L, and FT3 4.7 ± 0.5 pmol/L, P < 0.001
for each comparison between women and men). Positive anti-
TPO antibodies were more frequently present in women vs.
men (Supplemental Table 1). Moreover, when thyroid func-
tion was assessed according to positive anti-TPO antibody
status, TSH was found to be higher, whereas FT4 and FT3
were lower in subjects who were positive for anti-TPO
antibodies (Supplemental Table 1).
Multivariable linear regression analyses demonstrated
that TSH levels were associated inversely with current
cigarette smoking independent of age and sex with the
never smokers as reference category (Table 2; model 1).
Conversely, there were positive associations of FT4
(Table 2, model 2) and FT3 (Table 2, model 3) with current
cigarette smoking. However, as indicated by the standar-
dized regression coefficients (β), these associations were not
stronger in subjects who smoked >20 cigarettes per day vs.
subjects who smoked ≤20 cigarettes per day. We also per-
formed analysis with urinary cotinine concentrations as
objective reflection of smoke exposure (Table 3). The uni-
variate inverse correlations of TSH with urinary cotinine are
shown in Fig. 2a, whereas the positive correlations with
FT4 and FT3 are shown in Fig. 2b, c, respectively.
Given many differences in clinical and laboratory vari-
ables across the four categories of smoking behavior
(Table 1), we next performed multivariable linear regression
analyses in which we took account of a large number of
relevant clinical and laboratory variables. As shown in
Table 4, these analyses also showed that TSH levels
remained inversely, whereas FT4 and FT3 levels remained
associated positively with current smoking. These analyses
also did not demonstrate stronger associations in subjects
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who smoked >20 cigarettes per day vs. subjects who
smoked ≤20 cigarettes per day. Notably, these analyses also
demonstrated lower TSH, higher FT4, and higher FT3
levels in men, independent of anti-TPO antibody status, as
well as inverse associations of TSH, FT4, and FT3 with age.
FT4 was positively and FT3 was inversely associated with
BMI. Of further note, TSH levels were positively, whereas
FT3 levels were inversely associated with heavy alcohol
Table 1 Clinical and laboratory characteristics according to smoking status in 5766 participants of the PREVEND study





Urine cotinine (ng/mL)* 0 [0–0] 0 [0–0] 1191 [660–1721] 1744 [1310–2296] <0.001
Number (%) 1670 (29.0) 2436 (42.2) 1433 (24.9) 227 (3.9)
Age (years) 51 ± 12 56 ± 12 52 ± 11d 50 ± 8d <0.001
Sex (M: n; %) 750 (44.9) 1408 (57.8) 728 (50.8) 112 (49.3) <0.001
Systolic blood pressure (mm Hg) 125 ± 8 129 ± 19 123 ± 18d 124 ± 16e <0.001
Diastolic blood pressure (mm Hg) 72 ± 9 75 ± 9 73 ± 9d 75 ± 8b <0.001
Pulse pressure (mm Hg) 53 ± 13 54 ± 14 51 ± 11a,d 53 ± 12b,d <0.001
Pulse rate (beats/min) 68 ± 10 68 ± 10 69 ± 10c,d 74 ± 10a,d <0.001
BMI (kg/m2) 26.5 ± 4.4 27.2 ± 4.3 27.2 ± 4.3a 26.5 ± 4.5 <0.001
Diabetes (n; %) 91 (5.4) 167 (6.9) 69 (4.8) 12 (5.3) 0.050
History of CVD (n; %) 46 (2.8) 211 (8.7) 106 (7.4) 8 (3.5) <0.001
Antihypertensive drugs (n; %) 274 (16.4) 642 (26.4) 236 (16.5) 39 (17.2) <0.001
Glucose lowering drugs (n; %) 54 (3.2) 94 (3.9) 39 (2.7) 3 (1.3) 0.082
Lipid lowering drugs (n; %) 102 (6.1) 267 (11.0) 140 (9.8) 22 (9.7) <0.001
Alcohol consumption (g/day) <0.001
0/rarely (n; %) 515 (30.8) 503 (20.6) 333 (23.2) 54 (23.8)
0.1–10 (n; %) 352 (21.1) 377 (15.5) 219 (15.3) 14 (6.2)
10–30 (n; %) 557 (33.4) 778 (31.9) 458 (32.0) 56 (24.7)
>30 (n; %) 246 (14.7) 778 (31.9) 423 (29.5) 103 (45.3)
Glucose (mmol/L) 5.0 ± 1.2 5.1 ± 1.2 4.9 ± 1.1d 5.0 ± 1.2
eGFR (ml/min/1.73 m2) 95 ± 16 91 ± 18 91 ± 18a 97 ± 14d <0.001
UAE (mg/24 h) 7.8 (5.8–2.8) 9.2 (6.2–18.1) 8.8 (6.015.9)a,f 7.8 (5.8–12.8)a <0.001
Total cholesterol (mmol/L) 5.3 ± 1.0 5.4 ± 1.0 5.5 ± 1.0a 5.3 ± 1.0a,f <0.001
HDL cholesterol (mmol/L) 1.3 ± 0.3 1.3 ± 0.3b 1.2 ± 0.3a,e 1.3 ± 0.3b,e <0.001
Triglycerides (mmol/L) 1.3 (0.7–1.4) 1.1 (0.8–1.6) 1.2 (0.9–1.7)b 1.0 (0.7–1.4)b <0.001
TSH (mU/L) 1.68 (1.17–2.39) 1.62 (1.14–2.21) 1.44 (1.00–1.96)a,d 1.48 (0.94–1.91)a,d <0.001
FT4 (pmol/L) 15.7 ± 1.9 15.7 ± 1.9 15.9 ± 1.9c,d 15.9 ± 2.0 <0.001
FT3 (pmol/L) 4.9 ± 0.5 4.8 ± 0.5 4.9 ± 0.5a,d 5.0 ± 0.5a,d <0.001
Anti-TPO autoantibody titer (IU/mL) 9.8 (7.8–13.2) 9.6 (7.6–12.9) 11.4 (9.3–15.0)a,d 12.7 (10.7–16.3)a,d <0.001
Anti-TPO autoantibody positive (n; %) 150 (8.9) 163 (6.7) 110 (7.7) 22 (9.7) 0.036
Smoking status is categorized as never; former and current, which is divided in <20 and ≥20 cigarettes per day. Alcohol consumption is categorized
in 0/rarely; 0.10; 10–30 and >30 g per day. Ten grams of alcohol is equivalent to one alcoholic drink. Anti-TPO autoantibodies were not available
four subjects. Data are given in mean ± SD, medians (interquartile ranges), or in numbers (%). Between group differences are determined by
analysis of variance. Bonferroni method is applied to correct for multiple comparisons. P-value: P-value by analysis of variance or by χ2-analysis.
anti-TPO antithyroid peroxidase, BMI body mass index, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, FT4 free
thyroxine, FT3 freetriiodothyronine, HDL high density lipoproteins, TSH thyroid stimulating hormone, UAE urinary albumin excretion
Asterisk indicates that urine cotinine was measured in 5722 participants
aP < 0.001
bP < 0.01
cP < 0.05 vs. never smokers
dP < 0.001
eP < 0.01
fP < 0.05 vs. former smokers
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consumption. Table 5 shows the multivariable adjusted
results of thyroid function with urine cotinine concentra-
tions with an inverse association with TSH and positive
associations with FT4 and FT3, comparable to the results
with self-reported smoking status.
Discussion
In this large cohort of predominantly white European sub-
jects selected for strict euthyroidism, we documented that
current cigarette smoking is associated with modestly lower
TSH and higher FT3 levels compared with never and for-
mer smokers. In univariate analyses, FT4 levels were higher
in subjects who smoked ≤20 cigarettes per day vs. never and
former smokers. Multivariable linear regression analyses
confirmed these findings by demonstrating that TSH levels
were lower, whereas FT3 levels were higher in current
smokers even independent of a comprehensive number of
clinical and laboratory variables including alcohol
consumption. Likewise in these multivariable analyses, FT4
levels were higher in current smokers vs. never smokers.
Notably, we, did not observe an incremental effect of more
heavy smoking on these thyroid function parameters as
determined by self-report, as judged from the standardized
regression coefficients with the never smokers as reference
category. In addition, our study demonstrates an inverse
relationship of TSH and positive relationships with FT4 and
FT3 with urinary cotinine both in univariate and in multi-
variable analysis. While many earlier studies have revealed
that smoking is likely to affect thyroid function status in the
same direction as presently shown [9–15, 27, 28], the cur-
rent report represents to our knowledge the largest survey to
demonstrate that these associations are independent of
alcohol consumption with confirmation by urinary cotinine
concentrations as objective measure of smoke exposure.
It has been suggested that smoking may influence sym-
pathetic nervous activity and affect thyroid-directed auto-
immune responses [4, 9, 10]. In the current study, pulse rate
was elevated in both categories of current smokers, but
systolic blood pressure and pulse pressure were not ele-
vated. Thus, while sympathetic nervous activity is probably
to some extent enhanced in smokers [29], it remains
uncertain whether this would influence thyroid hormone
levels. With respect to anti-TPO autoantibodies: when
antibody titers were assessed as a continuous variable,
higher titers were observed in smokers who smoked ≤20
and >20 cigarettes per day vs. never and former smokers.
Further, the highest prevalence of positive anti-TPO auto-
antibodies was found in subjects who smoked >20 cigar-
ettes per day. These findings would be consistent with an
effect of smoking on thyroid-directed autoimmunity as for
example widely appreciated in Graves disease and thyroid-
associated ophthalmopathy [9, 10]. In comparison, previous
cohort studies have variably reported increased [15] and
decreased [30, 31] anti-TPO positivity in relation to
Table 2 Multivariable linear regression analyses demonstrating associations of thyroid function variables with cigarette smoking adjusted for age
and sex in 5766 participants of the PREVEND study
Model 1: TSH Model 2: FT4 Model 3: FT3
β P-value β P-value β P-value
Age −0.021 <0.001 −0.028 0.036 −0.167 <0.001
Sex (M vs. F) −0.075 <0.001 0.117 <0.001 0.286 <0.001
Smoking
Never (reference) former −0.037 0.020 0.026 0.10 −0.008 0.59
Current
≤20 cigarettes per day
−0.140 <0.001 0.043 0.006 0.055 <0.001
Current
>20 cigarettes per day
−0.083 <0.001 0.018 0.18 0.058 <0.001
Smoking status is categorized as never (reference category); former and current, which is divided in <20 and ≥20 cigarettes per day. β: standardized
regression coefficients
F female, FT4 free thyroxine, FT3 free triiodothyronine, M male, TSH thyroid stimulating hormone. TSH is loge transformed
Table 3 Multivariable linear regression analyses demonstrating
associations of thyroid function variables with cotinine levels
adjusted for age and sex in 5722 participants of the PREVEND study
Model 1: TSH Model 2: FT4 Model 3: FT3
β P-value β P-value β P-value
Age −0.007 0.56 −0.033 0.007 −0.137 <0.001
Sex
(M vs. F)
0.068 <0.001 −0.111 <0.001 −0.207 <0.001
Urinary
cotinine
−0.085 <0.001 0.038 0.002 0.045 <0.001
β: standardized regression coefficients. TSH and urinary cotinine are
loge transformed
F female, FT4 free thyroxine, FT3 free triiodothyronine, M male, TSH
thyroid stimulating hormone
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smoking behavior. In this regard it is also remarkable that
even under euthyroid conditions, subjects who were posi-
tive for anti-TPO autoantibodies had higher TSH, lower
FT4 and also lower FT3 levels compared with anti-TPO
autoantibody negative participants.
Partly opposite effects of alcohol consumption on thyroid
function parameters compared with cigarette smoking were
found, with higher TSH levels in subjects who reported
regular alcohol consumption, and lower FT3 levels in heavy
alcohol users. Hence, given that cigarette smoking may
coincide with more heavy alcohol use [18, 19], the present
results reinforce our assumption that it is relevant to take
account of alcohol consumption when evaluating the
association of smoking with thyroid function parameters.
Likewise, smoking and alcohol use also affects HDL cho-
lesterol levels in opposite directions [19, 32]. Although
earlier smaller-sized studies have suggested some effects of
alcohol use on thyroid function [16, 17], we are not aware
of large-scale population studies on the association of
alcohol consumption with thyroid function parameters.
Notably, however, we could not take account of other life
style factors such as exercise and nutrient intake, which my
coincide with alcohol consumption.
In the interpretation of the current findings it should be
considered that we defined euthyroidism by TSH, FT4 as
well as FT3 levels each within the reference range making
use of well-established electrochemiluminescent immu-
noassay systems. Our selection of euthyroid subjects based
on an FT3 value within the reference range, differs from
other cohort studies in which FT3 measurements were not
available [7, 33]. In multivariable analysis, we observed an
inverse association of TSH with age in agreement with
other reports from the Netherlands [2, 34]. Of note, we also
observed inverse associations of FT4 with age contrasting
these earlier findings [34] and even more so with respect to
FT3. These relationships were interpreted to be at least in
part attributable to increasing anti-TPO positivity with age
[1, 34]. The higher TSH, lower FT4 and FT3 levels in
women could be ascribed to female predisposition for anti-
TPO autoantibodies, although these associations were still
present after adjustment for anti-TPO positively. Iodine
intake may affect relationships of thyroid function para-
meters with age and sex [35]. In this regard it is relevant that
the North of the Netherlands represents an geographic area
of sufficient iodine intake, and was not identified as an area
with insufficient or borderline iodine intake in the past [36].
Several other methodological aspects of our study should
be acknowledged. We consider the comprehensive doc-
umentation of clinical and laboratory variables including
urinary cotinine, which is considered to be the gold standard
measure of cigarette smoke exposure, in a large cohort
including participants with a wide age range as well as
comparable participation of both sexes as a strength of our
study. On the other hand, the number of participants with
nonwhite ethnicity was low, hampering extrapolation to
other ethnicities. Further, we carried out a cross-sectional
study making that causal relationships could not be estab-
lished. Nonetheless, that tobacco exposure is probably
directly implicated in affecting thyroid function stems from
one of the first reports on this issue which demonstrated a
rise in TSH and a drop in T4 after smoking cessation [11].
Self-report on smoking behavior may result in inaccuracies
consequent to smoking denial or difficulty in recalling the
quantity of cigarettes smoked and exposure period [37],
although good agreement with cotinine measurement was
found in a previous report [38]. Such limitations could in
Fig. 2 Relationship of thyroid stimulating hormone (TSH) a, free
thyroxine (FT4) b, and free triiodothyronine c with urinary cotinine
excretion in 5722 participants of the PREVEND study. TSH and urinary
cotinine are loge transformed. Univariate correlation coefficients: TSH
with urinary cotinine: r=−0.118, P < 0.001; FT4 with urinary cotinine:
r= 0.044, P= 0.001; FT3 with urinary cotinine: r= 0.079, P < 0.001
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part be responsible for the fact that we did not observe
incremental effects of more heavy smoking as assessed by
questionnaire on TSH, FT4, and FT3. In fact our data
suggests linear relationships of smoke exposure with TSH
(inverse) as well as with FT4 and FT3 (positive).
In conclusion, this large cross-sectional study among
euthyroid predominantly white north European subjects
demonstrates that cigarette smoking is associated with
modest alterations in thyroid function as evidenced from
lower TSH, higher FT4, and higher FT3 levels. These
associations remain when taking account of clinical and
laboratory variables including partly opposing effects of
alcohol consumption.
Data availability
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Table 4 Multivariable linear
regression analyses
demonstrating independent
associations of thyroid function
variables with cigarette smoking
in 5766 participants of the
PREVEND study
Model 1: TSH Model 2: FT4 Model 3: FT3
β P-value β P-value β P-value
Age −0.087 <0.001 −0.098 <0.001 −0.221 <0.001
Sex (M vs. F) −0.051 0.001 0.126 <0.001 0.259 <0.001
Current smoking
Never (reference) former −0.027 0.10 −0.037 0.026 0.003 0.87
Current ≤20 cigarettes per day −0.134 <0.001 0.039 0.018 0.081 <0.001
Current >20 cigarettes per day −0.083 <0.001 0.025 0.076 0.068 <0.001
Alcohol consumption (g/day)
0/rarely (reference)
0.1–10 0.032 0.048 0.035 0.030 0.012 0.45
10–30 0.063 <0.001 0.013 0.46 −0.013 0.44
>30 0.043 0.015 0.004 0.81 −0.045 0.009
Positive anti-TPO autoantibodies (yes/no) 0.134 <0.001 −0.043 0.002 −0.024 0.059
Alcohol consumption is categorized in 0/rarely (reference category); 0.10; 10–30 and >30 g per day. β:
standardized regression coefficients. All models were adjusted for BMI, diabetes, history of CVD,
antihypertensive drugs, glucose-lowering drugs, lipid-lowering drugs, eGFR, UAE, total cholesterol, HDL
cholesterol, triglycerides. UAE, urinary albumin excretion. TSH, triglycerides and UAE are loge transformed
anti-TPO antithyroid peroxidase, F female, FT4 free thyroxine, FT3 free triiodothyronine, M male, TSH
thyroid stimulating hormone
Table 5 Multivariable linear
regression analyses
demonstrating independent
associations of thyroid function




Model 1: TSH Model 2: FT4 Model 3: FT3
β P-value β P-value β P-value
Age −0.086 <0.001 −0.106 <0.001 −0.224 <0.001
Sex (M vs. F) 0.053 0.001 −0.125 <0.001 −0.258 <0.001
Urinary cotinine −0.122 <0.001 0.044 0.002 0.091 <0.001
Alcohol consumption (g/day)
0/rarely (reference)
0.1–10 0.036 0.026 0.033 0.040 0.009 0.56
10–30 0.064 <0.001 0.009 0.62 −0.015 0.37
>30 0.040 0.023 −0.001 0.96 −0.044 0.010
Positive anti-TPO autoantibodies (yes/no) 0.134 <0.001 −0.043 0.002 −0.028 0.031
Alcohol consumption is categorized in 0/rarely (reference category); 0.10; 10–30 and >30 g per day. Urinary
cotinine data was measured in 5722 subjects. β: standardized regression coefficients. All models were
adjusted for BMI, diabetes, history of CVD, antihypertensive drugs, glucose-lowering drugs, lipid-lowering
drugs, eGFR, UAE, total cholesterol, HDL cholesterol, triglycerides. Cotinine, TSH, triglycerides and UAE
are loge transformed
anti-TPO antithyroid peroxidase, F female, FT4 free thyroxine, FT3 free triiodothyronine, M male, TSH
thyroid stimulating hormone
620 Endocrine (2020) 67:613–622
Acknowledgements The cotinine measurement for this research was
supported by a grant from the EU Joint Programme Initiative A
Healthy Diet for a Healthy Life (JPI HDHL), the Food Biomarker
Alliance (FOODBALL).
Authors’ contributions The authors’ responsibilities were as follows:
E.H. and J.H.J.B. provided data of medication use. J.K.-R and A.M.K.
supervised the thyroid function tests and anti-TPO measurements. D.T.
supervised the cotinine measurements. M.A.C. provided lipoprotein
and lipid measurements. E.G.G. and R.P.F.D. analyzed data/performed
statistical analysis; E.G.G., S.J.L.B., and R.P.F.D. interpreted the data;
E.G.G. and R.P.F.D. wrote the paper; E.G.G. and R.P.F.D. had pri-
mary responsibility for final content. All authors read and approved the
final paper.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.
W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T4, and
thyroid antibodies in the United States population (1988 to 1994):
National Health and Nutrition Examination Survey (NHANES
III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)
2. E.H. Hoogendoorn, A.R. Hermus, F. De VegT, H.A. Ross, A.L.
Verbeek, L.A. Kiemeney, D.W. Swinkels, F.C. Sweep, M. den
Heijer, Thyroid function and prevalence of anti-thyroperoxidase
antibodies in a population with borderline sufficient iodine intake:
influences of age and sex. Clin. Chem. 52, 104–111 (2006)
3. L.J. van Tienhoven‐Wind, R.P. Dullaart, Low–normal thyroid
function and the pathogenesis of common cardio‐metabolic dis-
orders. Eur. J. Clin. Investig. 45, 494–503 (2015)
4. P.N. Taylor, D. Albrecht, A. Scholz, G. Gutierrez-Buey, J.H.
Lazarus, C.M. Dayan, O.E. Okosieme, Global epidemiology of
hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 14,
301–316 (2018)
5. B.O. Åsvold, L.J. Vatten, T. Bjøro, D.C. Bauer, A. Bremner, A.R.
Cappola, G. Ceresini, W.P. Den Elzen, L. Ferrucci, O.H. Franco,
Thyroid function within the normal range and risk of coronary
heart disease: an individual participant data analysis of 14 cohorts.
JAMA Intern. Med. 175, 1037–1047 (2015)
6. R.P. Dullaart, R. De Vries, C. Roozendaal, A.C.M. Kobold, W.J.
Sluiter, Carotid artery intima media thickness is inversely related
to serum free thyroxine in euthyroid subjects. Clin. Endocrinol.
67, 668–673 (2007)
7. A. Bano, K. Dhana, L. Chaker, M. Kavousi, M.A. Ikram, F.U.
Mattace-Raso, R.P. Peeters, O.H. Franco, Association of thyroid
function with life expectancy with and without cardiovascular
disease: the Rotterdam study. JAMA Intern. Med. 177,
1650–1657 (2017)
8. L.J.N. van Tienhoven-Wind, E.G. Gruppen, W.J. Sluiter, S.J.L.
Bakker, R.P.F. Dullaart, Life expectancy is unaffected by thyroid
function parameters in euthyroid subjects: the PREVEND cohort
study. Eur. J. Intern. Med. 46, e36–e39 (2017)
9. J.B. Bertelsen, L. HEGEDÜS, Cigarette smoking and the thyroid.
Thyroid 4, 327–331 (1994)
10. W.M. Wiersinga, Smoking and thyroid. Clin. Endocrinol. 79,
145–151 (2013)
11. A. Melander, E. Nordenskjöld, B. Lundh, J. Thorell, Influence of
smoking on thyroid activity. Acta Med. Scand. 209, 41–43 (1981)
12. I. Meral, A. Arslan, A. Him, H. Arslan, Smoking-related altera-
tions in serum levels of thyroid hormones and insulin in female
and male students. Altern. Ther. Health Med. 21, 24–29 (2015)
13. R. Jorde, J. Sundsfjord, Serum TSH levels in smokers and non-
smokers. The 5th Tromsø study. Exp. Clin. Endocrinol. Diabetes
114, 343–347 (2006)
14. O.P. Soldin, B.E. Goughenour, S.Z. Gilbert, H.J. Landy, S.J.
Soldin, Thyroid hormone levels associated with active and passive
cigarette smoking. Thyroid 19, 817–823 (2009)
15. S. Kim, M.J. Kim, S.G. Yoon, J.P. Myong, H.W. Yu, Y.J. Chai, J.
Y. Choi, K.E. Lee, Impact of smoking on thyroid gland: dose-
related effect of urinary cotinine levels on thyroid function and
thyroid autoimmunity. Sci. Rep. 9, 4213 (2019)
16. P. Valeix, P. Faure, S. Bertrais, A. Vergnaud, L. Dauchet, S.
Hercberg, Effects of light to moderate alcohol consumption on
thyroid volume and thyroid function. Clin. Endocrinol. 68,
988–995 (2008)
17. S. Ozsoy, E. Esel, H.B. Izgi, S. Sofuoglu, Thyroid function in
early and late alcohol withdrawal: relationship with aggression,
family history, and onset age of alcoholism. Alcohol Alcohol 41,
515–521 (2006)
18. S.N. Slagter, J.V. van Vliet-Ostaptchouk, J.M. Vonk, H.M. Boe-
zen, R.P. Dullaart, A.C.M. Kobold, E.J. Feskens, A.P. van Beek,
K. van der, M. Melanie, B.H: Wolffenbuttel, Combined effects of
smoking and alcohol on metabolic syndrome: the LifeLines cohort
study. PLoS ONE 9, e96406 (2014)
19. E.G. Gruppen, S.J. Bakker, R.W. James, R.P. Dullaart, Serum
paraoxonase-1 activity is associated with light to moderate alcohol
consumption: the PREVEND cohort study. Am. J. Clin. Nutr.
108, 1283–1290 (2018)
20. S.E. Borggreve, H.L. Hillege, B.H. Wolffenbuttel, P.E. de Jong,
S.J. Bakker, G. van der Steege, A. van Tol, R.P. DullaartPRE-
VEND Study Group, The effect of cholesteryl ester transfer pro-
tein -629C->A promoter polymorphism on high-density
lipoprotein cholesterol is dependent on serum triglycerides. J.
Clin. Endocrinol. Metab. 90, 4198–4204 (2005).
21. H.J. Lambers Heerspink, A.H. Brantsma, D. de Zeeuw, S.J.
Bakker, P.E. de Jong, R.T. Gansevoort, PREVEND Study Group,
Albuminuria assessed from first-morning-void urine samples
versus 24-hour urine collections as a predictor of cardiovascular
morbidity and mortality. Am. J. Epidemiol. 168, 897–905 (2008)
22. S.H. Koning, R.T. Gansevoort, K.J. Mukamal, E.B. Rimm, S.J.
Bakker, M.M. Joosten, Alcohol consumption is inversely asso-
ciated with the risk of developing chronic kidney disease. Kidney
Int. 87, 1009–1016 (2015)
23. A. Abbasi, E. Corpeleijn, R.T. Gansevoort, R.O. Gans, H.L.
Hillege, R.P. Stolk, G. Navis, S.J. Bakker, R.P. Dullaart, Role of
HDL cholesterol and estimates of HDL particle composition in
future development of type 2 diabetes in the general population:
the PREVEND study. J. Clin. Endocrinol. Metab. 98,
E1352–E1359 (2013)
24. R. Sediq, J. van der Schans, A. Dotinga, R.A. Alingh, B. Wilffert,
J.H. Bos, C.C. Schuiling-Veninga, E. Hak, Concordance assess-
ment of self-reported medication use in the netherlands three-
generation lifelines Cohort study with the pharmacy database
Endocrine (2020) 67:613–622 621
iaDB. nl: the Pharmlines initiative. Clin. Epidemiol. 10, 981–989
(2018)
25. L.A. Inker, C.H. Schmid, H. Tighiouart, J.H. Eckfeldt, H.I.
Feldman, T. Greene, J.W. Kusek, J. Manzi, F. Van Lente, Y.L.
Zhang, Estimating glomerular filtration rate from serum creatinine
and cystatin C. N. Engl. J. Med. 367, 20–29 (2012)
26. S.P. Matyus, P.J. Braun, J. Wolak-Dinsmore, E.J. Jeyarajah, I.
Shalaurova, Y. Xu, S.M. Warner, T.S. Clement, M.A. Connelly,
T.J. Fischer, NMR measurement of LDL particle number using
the Vantera® clinical analyzer. Clin. Biochem. 47, 203–210 (2014)
27. J. Kang, E. Kong, J. Choi, Associations of urinary cotinine-
verified active and passive smoking with thyroid function: ana-
lysis of population-based nationally representative data. Thyroid
28, 583–592 (2018)
28. R.M. Belin, B.C. Astor, N.R. Powe, P.W. Ladenson, Smoke
exposure is associated with a lower prevalence of serum thyroid
autoantibodies and thyrotropin concentration elevation and a
higher prevalence of mild thyrotropin concentration suppression
in the third National Health and Nutrition Examination Survey
(NHANES III). J. Clin. Endocrinol. Metab. 89, 6077–6086 (2004)
29. P.E. Cryer, M.W. Haymond, J.V. Santiago, S.D. Shah, Nor-
epinephrine and epinephrine release and adrenergic mediation of
smoking-associated hemodynamic and metabolic events. N. Engl.
J. Med. 295, 573–577 (1976)
30. L. Mehran, A. Amouzgar, H. Delshad, F. Azizi, The association of
cigarette smoking with serum TSH concentration and thyroperox-
idase antibody. Exp. Clin. Endocrinol. Diabetes 120, 80–83 (2012)
31. S. Park, W.G. Kim, M.J. Jeon, M. Kim, H. Oh, M. Han, T.Y.
Kim, Y.K. Shong, W.B. Kim, Serum thyroid‐stimulating hormone
levels and smoking status: data from the Korean National Health
and Nutrition Examination Survey VI. Clin. Endocrinol 88,
969–976 (2018)
32. R.P. Dullaart, K. Hoogenberg, B.D. Dikkeschei, A. van Tol,
Higher plasma lipid transfer protein activities and unfavorable
lipoprotein changes in cigarette-smoking men. Arterioscler.
Thromb. 14, 1581–1585 (1994)
33. L. Chaker, C. Baumgartner, W.P. Den Elzen, T. Collet, M.A.
Ikram, M.R. Blum, A. Dehghan, C. Drechsler, R.N. Luben, M.L.
Portegies, Thyroid function within the reference range and the risk
of stroke: an individual participant data analysis. J. Clin. Endo-
crinol. Metab. 101, 4270–4282 (2016)
34. V. van de, C. Annenienke, R.T. Netea-Maier, F. de Vegt, H.A.
Ross, F.C. Sweep, L.A. Kiemeney, J.W. Smit, A.R. Hermus, M.
den Heijer, Associations between thyroid function and mortal-
ity: the influence of age. Eur. J. Endocrinol. 171, 183–191
(2014)
35. V. van de, C. Annenienke, R.T. Netea-Maier, J.W. Smit, R.
Kusters, S. van der, W.J. Jos, C.J. Pronk-Admiraal, M.M. Buijs,
C.H. Schoenmakers, S.G. Koehorst, M.J. de Groot, Thyrotropin
versus age relation as an indicator of historical iodine intake.
Thyroid 25, 629–634 (2015)
36. M. Geurts, J. Verkaik-Kloosterman. De jodiuminname van de
Nederlandse bevolking na verdere zoutverlaging in brood. RIVM.
(2014)
37. H.G. Kang, K.H. Kwon, I.W. Lee, B. Jung, E. Park, S. Jang,
Biochemically-verified smoking rate trends and factors associated
with inaccurate self-reporting of smoking habits in Korean
women. Asian Pac. J. Cancer Prev. 14, 6807–6812 (2013)
38. S.K. Kunutsor, J.M. Spee, L.M. Kieneker, R.T. Gansevoort, R.P.
Dullaart, A. Voerman, D.J. Touw, S.J. Bakker, Self‐Reported
smoking, urine cotinine, and risk of cardiovascular disease: find-
ings from the PREVEND (Prevention of Renal and Vascular End‐
Stage Disease) prospective cohort study. J. Am. Heart Assoc. 7,
e008726 (2018)
622 Endocrine (2020) 67:613–622
